Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
Hepamerz is a combination of two amino acids, l-ornithine and l-aspartate, believed to aid in the detoxification of ammonia in hepatic encephalopathy by promoting its conversion to urea and glutamine.
## Primary Indications
Treatment of latent and manifest hepatic encephalopathy (HE).
## Adult Dosing
* **Acute HE:** Typically initiated at 5g intravenously every 8 hours, potentially increased to 10g every 8 hours based on patient response and tolerance. Maximum daily dose is generally 30g.
* **Latent HE:** Typically 3g orally three times daily.
* **Dosing for specific formulations (e.g., injection vs. oral solution) may vary. Always consult product labeling.**
## Pediatric Dosing
* Information regarding the safety and efficacy of Hepamerz in pediatric patients is limited. Dosing in this population is generally not established and should be determined by a specialist based on individual circumstances.
## Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment beyond the underlying disease process addressed by the medication. However, careful monitoring is essential.
## Contraindications
* Severe renal insufficiency (creatinine clearance < 25 mL/min).
* Hypernatremia.
* Known hypersensitivity to l-ornithine or l-aspartate.
## Adverse Effects
* **Common:** Nausea, vomiting, abdominal pain, diarrhea, flatulence, fatigue.
* **Less Common:** Dizziness, headache, rash, pruritus, muscle pain.
* **Rare:** Hypernatremia (especially with IV administration in dehydrated patients).
## Key Drug Interactions
* No significant drug interactions have been definitively established. However, caution with other medications affecting electrolyte balance.
## Monitoring
* **Electrolytes:** Monitor serum electrolytes, particularly sodium and potassium, especially during intravenous therapy.
* **Renal function:** Monitor serum creatinine and BUN.
* **Hepatic function:** Monitor liver function tests.
* **Clinical status:** Assess for improvement in neurological symptoms of hepatic encephalopathy.
## Clinical Pearls
* The intravenous formulation is typically used for acute or severe hepatic encephalopathy, while oral formulations are for latent or chronic management.
* Slow infusion of the intravenous preparation is recommended to minimize potential side effects.
* Ensure adequate hydration, especially with IV administration, to prevent electrolyte disturbances.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before initiating or modifying drug therapy.*
